New research indicates that people who come off popular GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who end conventional lifestyle programs.
Published data in a prominent medical journal points out that while obese individuals can lose substantial amounts of their total mass while on the medication, the mass returns at an average rate of nearly a kilo each month after stopping.
"Users using such treatments need to be cognizant of the risk of fast rebound weight gain when the therapy is stopped," stated researcher Dr. Susan Jebb.
Such speed of recovery implies a return to pre-treatment mass within about one and a half years.
Analyzing Approaches
The research, which reviewed 37 of trials involving thousands of patients, contrasted the outcomes of these new drugs with conventional dieting.
Scientists note that people who shed pounds through lifestyle changes alone typically see a less rapid weight regain—around 100 grams monthly—post-intervention.
The Reason for the Fast Regain
Nutrition scientists believe the mode of action of the injections accounts for the heightened regain.
The injections mimic a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Artificially providing the hormone concentrations far above than normal may cause the system to generate a reduced amount of its own natural GLP-1, and could reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Stopping of this medication leads to appetite is no longer kept in check, making overeating a significant risk."
A Chronic Disease?
The NHS suggest the injections for people with obesity-related medical conditions, alongside recommended lifestyle changes.
Professionals contend that, given the high risk of relapse, the treatment is often ongoing.
This view is supported by drug manufacturers, who say that the findings "underscore the chronic character of excess weight," comparing it to managing diseases like high blood pressure.
Patient Testimonies
People who have come off the jabs describe a intense resurgence of hunger.
"It felt as if a switch flipping and I was suddenly starving," recalled one woman.
This challenge is compounded if patients have not established lasting lifestyle or habit changes during treatment.
Significant Use
Survey data indicate that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow.
- Use is more common among females than men.
- The 40s and 50s age group shows the greatest usage rates.
- Many access the medications through private prescriptions rather than public health services.
In conclusion, researchers emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a standalone solution and long-term success likely depends on ongoing lifestyle changes.
